Sep. 1 at 7:27 PM
Just for fun attached is a list of all 15 new commercial-stage oncology focused bios (still indepedent) with first FDA approvals going back 2 years (generously rounded for DCTH).
A review of all 60 new such bios since 1/1/2013 shows those that sell within 2 years of FDA approval generate the best gains for shareholders.
Again just for fun, if we had to guess the most likely near-term M&A candidates from this peer group, we'd guess:
$SNDX
$DAWN
$ZYME
$AUTL
We'd say potential
$IOVA suitors will wait for the Lung data later this year, GERN for the MDS data & IMCR for the melanoma data.
Recall SWTX peer Year 4 M&A revenue multiples per SWTX's bankers were 2.3 to 5.2X (again Year 4) acquired for
$3.5B (which was considered disappointing).
This is not investment advice.
